Special Issue "Antibody Engineering for Cancer Immunotherapy"

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• The development of antibody engineering for cancer immunotherapy has rapidly advanced since the introduction of Rituximab in the late 1990s.
• Rituximab, the first chimeric monoclonal antibody, marked a significant milestone in treating non-Hodgkin lymphoma.
• The field has expanded dramatically, with numerous antibody therapeutics now approved and in clinical development.

Discussion:

• The success of early antibody therapies has spurred innovation in designing novel antibody constructs.
• Engineering approaches aim to enhance antibody efficacy, specificity, and safety for cancer treatment.
• The growing pipeline of antibody therapeutics highlights their increasing importance in clinical oncology.

Key Insights:

• Over 50 antibody therapeutics have gained approval in the USA and EU.
• Hundreds of antibody-based cancer therapies are currently undergoing clinical trials.
• The field demonstrates a robust and expanding therapeutic landscape for antibody-driven cancer immunotherapy.

Outlook:

• Continued advancements in antibody engineering promise more targeted and effective cancer immunotherapies.
• Future research will likely focus on overcoming resistance mechanisms and expanding treatment applications.
• The trajectory suggests antibody therapeutics will play an increasingly central role in personalized cancer care.